Melanotan II

Melanotan II (MTII) is a synthetic peptide analog of alpha-melanocyte-stimulating hormone (α-MSH) and acts as a non-selective melanocortin receptor agonist Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs) (research review). It was originally synthesized in the 1990s as part of programs to develop melanocortin receptor ligands, and early human studies confirmed it could increase skin pigmentation (tanning) Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study+1.

Beyond tanning, research has explored its effects on sexual function, appetite, and energy expenditure, driven by its activity at central melanocortin receptors Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II+1. Today, MTII is not an approved medicine but is widely referenced in the research literature and also encountered in unregulated appearance- and performance-enhancement markets, where product quality can be highly variable Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet+1.

Melanotan II works by mimicking α-MSH, a natural hormone that activates melanocortin receptors (research article). It binds to multiple receptor subtypes, particularly MC1R in melanocytes (skin pigment cells) and MC4R/MC3R in the brain and nervous system Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs).

When MTII activates MC1R in the skin, it triggers a cascade that increases production of eumelanin, the dark pigment responsible for tanning Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs). This is the same pathway the body uses to tan in response to UV exposure, but MTII can stimulate it without sunlight (though UV exposure amplifies the effect) Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

In the brain, MTII's activation of MC4R and MC3R suppresses appetite and increases energy expenditure, as shown in animal studies Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression+1. These receptors also influence sexual function: MC4R activation in the central nervous system can promote erections, which is why MTII has been investigated for erectile dysfunction Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II+1. Recent research suggests that β-arrestin 2 signaling is important for the metabolic effects of MC4R activation, indicating that MTII’s actions are more complex than simply turning on a receptor 98-OR: Melanocortin 4 Receptor–Mediated Effects Require Beta-Arrestin 2 Signaling.

Other effects, like increased neuronal activity in oxytocin-producing brain regions and changes in glucose handling, further illustrate the broad reach of melanocortin signaling Effect of Melanotan‐II on Brain Fos Immunoreactivity and Oxytocin Neuronal Activity and Secretion in Rats+1.

Research studies and user reports have documented several effects of Melanotan II. The most prominent is increased skin pigmentation. In a phase I clinical study, MTII injections led to measurable tanning (human phase I study) Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study. In community settings, users consistently report darker skin, especially when combined with UV exposure Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

Pro-erectile effects have been documented in human studies. In men with organic erectile dysfunction, MTII produced erections after injection Melanocortin receptor agonists, penile erection, and sexual motivation: human studies with Melanotan II+1. This effect is centrally mediated and can occur without sexual stimulation, which also explains why spontaneous erections and increased libido are common user experiences Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

Appetite reduction is well supported in animal models. MTII reliably reduces food intake in rodents, including in diet-induced obese models Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression+1. Some of this effect may involve nausea or malaise rather than pure satiety, as indicated by aversion studies Assessment of the aversive consequences of acute and chronic administration of the melanocortin agonist, MTII.

Other documented effects in preclinical studies include increased thermogenesis (heat production) and energy expenditure, improvements in glucose tolerance, and reduced glycosuria via a brain-kidney axis Unabated anorexic and enhanced thermogenic responses to melanotan II in diet-induced obese rats despite reduced melanocortin 3 and 4 receptor expression+2. Behavioral studies in rodents have also suggested possible reductions in alcohol intake and improvements in autism-like behaviors, but human evidence is lacking Melanotan-II reverses autistic features in a maternal immune activation mouse model of autism+1.

Notably, some effects are not always beneficial. Case reports describe significant adverse events including priapism, renal infarction, rhabdomyolysis, and potential links to melanoma development, which are discussed in the safety section Melanotan II: a possible cause of renal infarction: review of the literature and case report+3.

There is no approved medical protocol for Melanotan II. Most research has used subcutaneous injection because it allows systemic absorption. Human studies have used parenteral routes, but doses and schedules have varied Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study+3 (human studies).

In community protocols, which are not clinically validated, a common approach is to start with a low dose (0.125-0.25 mg) for the first few days to assess tolerance, then increase to a daily dose of 0.25-0.5 mg for 10-20 days until the desired pigmentation is achieved, followed by a maintenance phase of 0.25-0.5 mg two to three times per week Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. These self-experimentation protocols often incorporate UV exposure, which complicates the assessment of MTII's standalone effect Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

It is important to note that the actual content of vials sold online can be significantly lower than labeled; one analysis found vials claimed to contain 10 mg actually held 4.32-8.84 mg, with up to 5.9% impurities Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. This makes dose standardization difficult and increases risk.

Melanotan II is typically supplied as a lyophilized (freeze-dried) powder in vials. For research use, it is reconstituted with bacteriostatic water for multi-dose vials. Sterile water may be used if the entire vial will be consumed within a week Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

To reconstitute, slowly inject the diluent into the vial, allowing it to run down the wall, and gently swirl until dissolved. Do not shake vigorously, as this can damage the peptide. Once reconstituted, store the vial in the refrigerator (2-8°C) and protect from light. With bacteriostatic water, the solution is typically considered usable for up to 30 days if handled aseptically; with sterile water, the window is shorter (7-14 days) Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

Unreconstituted vials should be stored in a cool, dry place, ideally refrigerated or frozen for long-term stability. Avoid repeated freeze-thaw cycles. The quality of illicit products varies; independent testing has found inconsistencies in peptide content and purity, so handling should assume variable potency Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet.

For precise dosing, an interactive reconstitution calculator is available in this section to help determine volumes based on vial size and desired dose. Qualitative guidance on storage and handling is provided above, but all quantitative calculations should reference that tool.

Pro-erectile agents – Combining MTII with PDE5 inhibitors (sildenafil, tadalafil) or other erectogenic drugs can increase the risk of priapism, a prolonged and painful erection requiring emergency treatment. Human studies confirm MTII's erectogenic activity, and case reports document priapism after use Evaluation of Melanotan-II, a superpotent cyclic melanotropic peptide in a pilot phase-I clinical study+2 (human studies, case reports). Caution is warranted.

Cardiovascular drugs – Melanocortin activation can raise blood pressure and heart rate in animal models, particularly when nitric oxide pathways are compromised SYSTEMIC BUT NOT CENTRAL NERVOUS SYSTEM NITRIC OXIDE SYNTHASE INHIBITION EXACERBATES THE HYPERTENSIVE EFFECTS OF CHRONIC MELANOCORTIN-3/4 RECEPTOR ACTIVATION. Co-administration with stimulants, decongestants, or vasoconstrictive agents may amplify these effects. Users on antihypertensives should monitor blood pressure closely.

Antidiabetic agents – MTII improves glucose disposal in animal studies and may cause additive hypoglycemia when combined with insulin, sulfonylureas, or GLP-1 agonists The melanocortin agonist melanotan II increases insulin sensitivity in OLETF rats+1. Appetite suppression could also be excessive, leading to inadequate caloric intake.

Immunomodulators – Melanocortin receptors are present on immune cells, but clinical data on interactions with immunomodulatory drugs are lacking Reciprocal regulation of human natural killer cells and macrophages associated with distinct immune synapses+1.

Supplements – Yohimbine, high-dose caffeine, and other stimulants may compound cardiovascular effects. L-arginine and other nitric oxide boosters could theoretically increase priapism risk. UV exposure, while not a supplement, is a major behavioral interaction that amplifies skin changes and complicates melanoma risk assessment Melanotan II User Experience: A Qualitative Study of Online Discussion Forums+1.

Research on long-term Melanotan II cycling is absent. Users often adopt intermittent patterns to manage side effects and reduce cumulative exposure, but these are based on community practice rather than clinical evidence Melanotan II User Experience: A Qualitative Study of Online Discussion Forums.

A typical self-reported cycle involves a loading phase of daily injections for 1-3 weeks until the desired tan is achieved, followed by a maintenance phase of 2-3 injections per week. Some users cycle on and off for 4-8 weeks at a time, often aligned with summer or bodybuilding phases Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Because pigmentation can persist for weeks after stopping, maintenance doses are usually lower and less frequent.

The rationale for cycling includes limiting nausea, spontaneous erections, and other acute side effects, as well as concern over darkening of moles and potential melanoma risk Melanotan II User Experience: A Qualitative Study of Online Discussion Forums+1. Since MTII is not approved for human use, there is no established safe duration; case reports of serious adverse events after varying periods of use suggest individual responses can be unpredictable Melanotan II: a possible cause of renal infarction: review of the literature and case report+2.

In physique and bodybuilding contexts, Melanotan II is sometimes combined with other peptides and supplements. However, formal research on these stacks is lacking, and most information comes from anecdotal reports.

PT-141 (bremelanotide) – Both are melanocortin agonists, and stacking them can intensify nausea, flushing, and erectile effects, potentially leading to priapism. This combination is generally discouraged due to overlapping mechanisms Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs)+1.

GLP-1 agonists (semaglutide, tirzepatide) – Combined use may lead to excessive appetite suppression and nausea, making it difficult to maintain adequate nutrition. The additive metabolic effects are unstudied Melanoma In-Situ Associated with Melanotan Ii Use.

Growth hormone secretagogues (CJC-1295, ipamorelin) – No direct pharmacodynamic interactions are known, but the combined impact on appetite, energy expenditure, and side effect profiles can be challenging to manage. Users often add one compound at a time to identify the source of any adverse reactions.

Recovery peptides (BPC-157, TB-500) – There is no known direct conflict, but these do not mitigate the specific risks of MTII (e.g., priapism, renal issues, pigmentation changes). They should not be viewed as protective stack components.

In general, adding multiple new compounds simultaneously confounds the ability to attribute side effects. If a stack is being used, introduce one substance at a time with a washout period between additions.

Melanotan II is not approved by the FDA or any other regulatory agency for tanning, weight loss, or sexual dysfunction Recommended Tool Compounds for the Melanocortin Receptor (MCR) G Protein-Coupled Receptors (GPCRs)+2. It is categorized as an unlicensed, unregulated substance, and products sold online are often labeled 'for research purposes only' in an attempt to circumvent drug laws. In reality, these products are frequently underdosed and impure Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet+1.

In the United Kingdom, the MHRA has warned consumers not to use Melanotan, stating it is an unlicensed medicine sold illegally Melanotan products not safe for tanning+1. Australian dermatologists have raised public health concerns over its unregulated use The unregulated use of melanotan‐II is of public health interest to Australian dermatologists. Across Europe, it is treated as an unapproved drug, and personal importation may violate customs regulations.

For athletes, while Melanotan II is not explicitly listed on the WADA Prohibited List in the provided sources, it falls under the category of unapproved substances and its use in sport is strongly discouraged. The risk of contaminated or mislabeled products also raises anti-doping concerns Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet+1.

The safety profile of Melanotan II is dominated by case reports and user experiences, as no large-scale clinical trials have been conducted (case reports, user reports).

Common side effects – Nausea, facial flushing, spontaneous erections, and increased libido are frequently reported Melanotan II User Experience: A Qualitative Study of Online Discussion Forums. Darkening of moles and generalized skin pigmentation is expected and often the desired effect, but rapid or irregular changes in pigmented lesions can be a safety concern Melanotan II User Experience: A Qualitative Study of Online Discussion Forums+1.

Serious adverse events – Multiple case reports associate MTII use with severe outcomes including ischemic priapism Determination of melanotan‐II in rat plasma by liquid chromatography/tandem mass spectrometry: determination of pharmacokinetic parameters in rat following intravenous administration+1, renal infarction Melanotan II: a possible cause of renal infarction: review of the literature and case report, and systemic toxicity with rhabdomyolysis Melanotan II injection resulting in systemic toxicity and rhabdomyolysis. These are rare but potentially life-threatening.

Melanoma concerns – Several reports describe melanoma or melanoma in situ diagnosed shortly after MTII use, often in individuals who also used UV tanning Melanoma Associated with the Use of Melanotan-II+2. Additionally, one case report describes oral mucosal pigmentation after injection , and another raises the possibility of oral mucosal malignant melanoma associated with nasal spray formulations , highlighting that pigmentation changes can occur in non-skin mucosal tissues. While a direct causal link is not established, the peptide's ability to stimulate melanocytes and darken existing nevi means that it could accelerate the growth or detection of pre-existing melanocytic lesions. Shared risk factors like fair skin and sunbed use further complicate the picture.

Contraindications – People with a personal or family history of melanoma, multiple atypical nevi, or conditions like FAMMM syndrome should avoid MTII. It is also contraindicated in anyone with a history of priapism, sickle cell disease, or severe cardiovascular disease. Use during pregnancy or breastfeeding is not supported by any safety data.

Product quality adds another layer of risk: vials sold online may contain less active ingredient than claimed and up to 5.9% unknown impurities Identification and characterization by LC-UV-MS/MS of melanotan II skin-tanning products sold illegally on the Internet. This makes adverse reactions unpredictable. Regular skin monitoring by a dermatologist is advised for anyone using MTII, with prompt reporting of any new or changing lesions Depigmented facial and neck patches following melanotan use in a patient with atopic dermatitis and alopecia areata+1.